Dr Reddy's Labs bags DCGI emergency use nod for single dose Sputnik Light in India
The standalone Sputnik Light vaccine is the latest vaccine to be approved by the DCGI as part of the India's national inoculation effort against COVID-19.
Hyderabad: Pharma major, Dr. Reddy's Laboratories Ltd., today announced that the Drugs Controller General of India (DCGI) has granted approval to the single-shot Sputnik Light vaccine for restricted use in emergency situation in India.
Sputnik Light is a one-dose vaccine and the same as the first component—recombinant human adenovirus serotype number 26 (rAd26)—of the two-dose Sputnik V vaccine. Following its Phase III clinical trial of the single-shot Sputnik Light vaccine in India, Dr. Reddy's had submitted its application for approval to the DCGI in December 2021, in addition to data from clinical trial in Russia. The standalone Sputnik Light vaccine is the latest vaccine to be approved by the DCGI as part of India's national inoculation effort against COVID-19.
Sputnik Light is the second COVID-19 vaccine to be made available in India by Dr. Reddy's. Sputnik Light has been approved in over 30 countries around the world including Argentina, UAE, Philippines and Russia.
Earlier this year, an independent comparative study conducted by the Spallanzani Institute in Italy showed that Sputnik V demonstrates strong protection against the Omicron variant, with over two times higher virus neutralising activity compared to the Pfizer vaccine. The data supports the results of the recent laboratory study by the Gamaleya Center demonstrating that Sputnik V induces robust neutralising antibody response to the Omicron variant, further strengthened by Sputnik Light as a booster .
In September 2020, Dr. Reddy's partnered with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V and distribute the vaccine in India. In April 2021, the DCGI granted approval to the two-dose Sputnik V vaccine for restricted use in emergency situation in India.
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Read also: Dr Reddys seeks DCGI nod for Sputnik Light phase 3 trial as booster dose
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.